AAV-BA Jumps Joyfully on Vaccine Optimism for Early-Than-Expected Economic Recovery
AAV-BA Jumps Joyfully on Vaccine Optimism for Early-Than-Expected Economic Recovery.
AAV-BA Jumps Joyfully on Vaccine Optimism for Early-Than-Expected Economic Recovery.
14 ธ.ค. 2563

The share price of AAV and BA made a high jump in the morning session on Monday as investors traded on optimism that the coronavirus situation would recover quickly after the UK and U.S. approved Pfizer/BioNTech coronavirus vaccine.
 
The share price of Asia Aviation Public Company Limited (AAV) closed the Monday’s morning session at ฿2.82/share, increased ฿0.36/share or 14.63% with a trading value of 655 million baht. The highest share price in the morning session was ฿3.06/share and the lowest was ฿2.54/share.
The share price of Bangkok Airways Public Company Limited (BA) closed at ฿7.50/share, increased ฿0.80/share or 11.94% with a trading value of 59 million baht. The highest share price in the morning session was ฿7.60/share and the lowest was ฿6.70/share.
Meanwhile, the share price of Nok Airlines Public Company Limited (NOK) dropped ฿0.05/share or 6.10% to close the morning session at ฿0.77/share with a trading value of 1.6 million baht. However, the share price came out of a high trading volume on the previous trading day with a gain of ฿0.16/share or 24.24% with a trading value of 1.4 million baht.
 
Late Friday last week, the U.S. Food and Drug Administration has approved Pfizer and BioNTech’s coronavirus vaccine for an emergency use as the pandemic reaches a critical point in the United States.
The authorization is for those aged 16 and older.
“The FDA’s authorization for emergency use of the first Covid-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world,” wrote FDA Commissioner Stephen M. Hahn, M.D. in a statement.
 
A few days prior to the U.S. approval, the U.K. government started to roll out its first batch of coronavirus vaccine to the public, mainly on elderly, on Tuesday after its Medicines and Healthcare products Regulatory Agency said the Pfizer/BioNTech vaccine is up to 95% effective for protection from Covid-19, therefore it’s safe for launch to the public.